Novo Nordisk cut its full-year earnings outlook after reporting weaker-than-expected quarterly sales of its popular weight-loss drug Wegovy, raising concerns among investors about growing competition from Eli Lilly. The results end a prolonged run of positive earnings news from Europe’s most valuable listed company.